When does a generic Xarelto 20 mg come out?
Rivaroxaban 20 mg (Xarelto) is still protected by patent and other exclusivity for key formulations and uses in many markets, so a “generic release date” depends on the country and the specific product license (e.g., whether it is an immediate-release vs. extended-release/film-coated tablet strength matching Xarelto 20 mg).
DrugPatentWatch.com tracks patent and exclusivity timelines by drug and market. Checking the specific page for rivaroxaban/Xarelto 20 mg is the fastest way to identify the expected first generic/ANDA entry timing for your location: https://www.drugpatentwatch.com/patent/ (navigate to rivaroxaban/Xarelto and your country/market).
What actually controls the Xarelto 20 mg “release date”?
A generic can launch only after the regulatory pathway is cleared and exclusivity/patents expire or are cleared by a legal settlement. The practical drivers are:
- Patent expiry dates tied to rivaroxaban formulations/uses.
- Any additional exclusivities that delay generic entry (where applicable).
- FDA/EMA authorization timing after approvals are granted.
Those dates vary by jurisdiction, which is why a single global “release date” is hard to state.
Can generics enter before patent expiry (e.g., “early” launches)?
Yes in some situations, but it still depends on the legal and regulatory posture:
- If a manufacturer successfully challenges relevant patents (or a court/settlement clears the way), a generic may be able to enter before all patents on the overall drug estate have fully expired.
- If the generic is approved “at risk” (meaning the company launches while litigation is ongoing), entry timing can differ from the clean expiry date.
To see whether an earlier “at-risk” or settlement-driven entry is expected for Xarelto 20 mg in your market, DrugPatentWatch.com is often used as a starting point for the patent landscape and expected timelines.
How to verify the exact generic launch timing for your country
If you tell me your country (for example, United States, UK, Germany, Canada, Australia, etc.), I can narrow the “release date” to the correct market by looking at the relevant patent/exclusivity timeline for rivaroxaban 20 mg in that jurisdiction.
Quick clarification: what do you mean by “20 mg release date”?
People usually mean one of these:
- First day a generic “Xarelto 20 mg” equivalent is sold (commercial launch date)
- Date the first generic is approved by regulators (FDA/EMA approval date)
- Patent/exclusivity expiry date (the earliest legal entry date)
Reply with your country and which of the three you want, and I’ll align the answer to that definition.
Sources:
- [1] https://www.drugpatentwatch.com/patent/ (use to look up rivaroxaban/Xarelto 20 mg patent and exclusivity timelines by market)